Embracing the Promise of Oncolytic Virus Immunotherapy – Drug Discovery & Development
Drug Discovery & Development |
Embracing the Promise of Oncolytic Virus Immunotherapy
Drug Discovery & Development Despite decades of research, and significant medical breakthroughs, cancer mortality rates remain high, while efficacious therapeutic options vary greatly across cancer types. This heterogeneity in effective treatment options is due in part to cancer’s … |
Drug Discovery & Development |
Embracing the Promise of Oncolytic Virus Immunotherapy
Drug Discovery & Development Despite decades of research, and significant medical breakthroughs, cancer mortality rates remain high, while efficacious therapeutic options vary greatly across cancer types. This heterogeneity in effective treatment options is due in part to cancer’s … |
OncLive |
FDA Puts Clinical Holds on “Off-the-Shelf” CAR–T Trials
OncLive Following the death of a 78-year-old man being treated for blastic plasmacytoid dendritic cell neoplasm (BPDCN), the FDA placed clinical holds on 2 phase I trials investigating a gene-edited allogeneic CAR T-cell (UCART) therapy known as UCART123. FDA hits Cellectis’ off-the-shelf CAR–T program with clinical hold after first patient treated in phase 1 trial diesFierceBiotech Patient Death Triggers FDA Hold For Cellectis’s “Off the Shelf” CAR–TXconomy Genetically Modified Immune Cells Have Killed a Patient, Halting Two Cutting-Edge TrialsMIT Technology Review BioPharma Dive –Genetic Engineering & Biotechnology News –P&T Community all 22 news articles » |
OncLive |
FDA Puts Clinical Holds on “Off-the-Shelf” CAR–T Trials
OncLive Following the death of a 78-year-old man being treated for blastic plasmacytoid dendritic cell neoplasm (BPDCN), the FDA placed clinical holds on 2 phase I trials investigating a gene-edited allogeneic CAR T-cell (UCART) therapy known as UCART123. FDA hits Cellectis’ off-the-shelf CAR-T program with clinical hold …FierceBiotech Patient Death Triggers FDA Hold For Cellectis’s “Off the Shelf” CAR–TXconomy Genetically Modified Immune Cells Have Killed a Patient, Halting Two Cutting-Edge TrialsMIT Technology Review BioPharma Dive –Genetic Engineering & Biotechnology News –P&T Community all 22 news articles » |
|
Cancer drug research moving fast in immunotherapy field
SFGate “CAR–T therapy is in open water, vastly uncharted,” said Jay Bradner, president of Novartis Institutes for BioMedical Research, which is leading cell-therapy development at the Swiss drugmaker. “We have to make bold bets on where we can make the … |
Xconomy |
Two CAR-T Cancer Immunotherapy Trials on Clinical Hold After Patient Death
P&T Community The FDA has placed a clinical hold on two gene-edited allogeneic CAR T-cell (UCART) phase 1 studies being conducted by Cellectis after the report of a patient death. The studies are evaluating UCART123 immunotherapy in patients with acute myeloid … Patient Death Triggers FDA Hold For Cellectis’s “Off the Shelf” CAR-TXconomy Here’s Why Cellectis SA Fell as Much as 31.6% TodayMotley Fool After Patient Death, FDA Places Clinical Hold on Cellectis CAR-T Candidate UCART123Genetic Engineering & Biotechnology News |